Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MER 511

Drug Profile

MER 511

Alternative Names: MER-511

Latest Information Update: 22 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merida Biosciences
  • Class Immunoglobulin Fc fragments; Immunotherapies; Recombinant proteins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Graves' disease

Most Recent Events

  • 07 Jan 2026 Merida Biosciences has 3 patent pending applications, two for "Molecules for controlling autoimmune response" (WO 202 503 000 3A2) (WO 202 503 000 0A1) and one for "Molecules for controlling immune response" (WO 202 503 000 9A1) in the multiple countries worldwide prior to January 2026
  • 08 Dec 2025 Phase-I clinical trials in Graves' disease in USA (IV) (NCT07305818)
  • 08 Dec 2025 Phase-I clinical trials in Graves' disease in USA (SC) (NCT07305818)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top